Single-use bioprocessing, a fast-developing technology, is used to provide disposable bioprocessing tools and supplies for the production of biopharmaceutical molecules such as recombinant proteins, monoclonal antibodies, vaccines, and stem cells. A bioprocess produces desired products using living cells or their parts, such as enzymes, bacteria, and others. The fundamental motivation for using single-use bioprocessing technology in bioprocesses is to cut the expense of labor-intensive processes like sterilization, cleaning, and upkeep of steel-based bioreactor systems.
In 2021, the market for single-use bioprocessing was USD 14.83 billion, and by 2030, it will reach USD 55.78 billion, growing at a 15.86% CAGR during the forecast period.
Market Dynamics
Drivers
Faster implementation and a decreased danger of product cross-contamination, rising demand for biopharmaceuticals, lower prices, and a less environmental effect of single-use bioprocessing technologies are boosting the market's expansion.
The increasing rate of chronic diseases has increased the demand for biopharmaceuticals. As a result, there will be a greater need for single-use technologies, which will contribute to the market's growth. For instance, the Food and Drug Administration reports that 14 biologics were authorized to treat different chronic conditions in 2021. As a result, the growing number of biological approvals will raise the biopharmaceutical production process, increasing the use and adoption of single-use bioprocessing technologies and systems.
Restraints
The industry's lack of standardization and worries about the consistency and dependability of single-use bioprocessing equipment is limiting market revenue growth. The high cost of single-use bioprocessing equipment and a shortage of competent employees to operate these systems further limit the market's revenue development.
Opportunity
China & India are the two countries with the highest potential markets for single-use bioprocessing systems. This is brought on by favorable government policies, increased private investment, an aging population, a marked increase in outsourcing to developing Asian markets, and the presence of skilled labor in these countries. India, Japan, Brazil, and APAC are likely the new income sources for market participants. The significant investment in bio-manufacturing infrastructure is also a key factor in these industries' excellent development potential and will provide a lot of future chances for the expansion of the single-use bioprocessing industry.
Market Segmentation
By Product
With a significant revenue share in 2022, the media bags and containers segment led the global single-use bioprocessing market. In the biopharmaceutical business, the usage of media bags and containers offers inexpensive initial investment, reduced waste emission, and reduced operational costs. The single-use media bags and containers also offer durability and temperature resistance. As a result, the widespread usage of media bags and containers in the biopharmaceutical industry has contributed to the segment's recent expansion.
By Application
In 2022, the filtration category dominated the global single-use bioprocessing market. Due to its effective filtering even at large scales, single-use bioprocessing systems are becoming more and more popular infiltration. It is utilized for ultrafiltration, biomolecular polishing, and the removal of bioburden.
By End-User
In 2022, the biopharmaceutical manufacturers segment led the entire market due to the rapidly expanding biopharmaceutical industry. Additionally, single-use bioprocessing systems have been adopted by more than 80% of biopharmaceutical firms because they are more affordable, effective, and dependable.
Regional Analysis
In 2022, North America was the major market contributor, with a share of more than 34.2% due to the region's established pharmaceutical and biomanufacturing sector and extensive R&D efforts. A growing emphasis on vaccine production fuels the need for single-use bioprocessing equipment to support local efforts at disease prevention.
The Asia Pacific region will develop at the fastest rate of 16.71%. Multiple investments from numerous international corporations have been made in the region's expanding bioprocessing market.
Key Players
- Avantor
- Sartorius Stedim Biotech S.A.
- Danaher Corporation
- Thermo Fisher Scientific
- Getinge AB
- Corning
- Merck KGaA
- Eppendorf AG
- Entegris
- PBS Biotech, Inc.
- CESCO Bioengineering Co. Ltd.
- Cellexus
- Distek, Inc.
- G&G Technologies
- Solida Biotech GmbH
- ABEC, Inc.
- Satake Chemical Equipment Mfg., Ltd.
- Stobbe Pharma GmbH
- Able Corporation & Biott Corporation
- OmniBRx Biotechnologies
- Celltainer Biotech
- Pierre Guerin
- Meissner Filtration Products, Inc.
- Bbi-Biotech GmbH
- Catalent
- Kuhner AG
In 2021, the market for single-use bioprocessing was USD 14.83 billion, and by 2030, it will reach USD 55.78 billion, growing at a 15.86% CAGR during the forecast period. The single-use bioprocessing market will develop due to the surge in demand for biopharmaceuticals.
Related Reports:
Recombinant DNA Technology Market Report - The global recombinant DNA technology market will witness a robust CAGR of 7.7%, valued at $707.20 billion in 2021, expected to appreciate and reach $1378.76 billion by 2030, confirms Strategic Market Research.